Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Solana Company stock logo
HSDT
Solana
$1.63
-0.3%
$2.32
$1.19
▼
$4.36
$102.82M1.1623,709 shs231,770 shs
LITS
Lite Strategy
$0.81
+1.6%
$1.15
$0.69
▼
$1.99
$23.75M0.17280,907 shs148,449 shs
KindlyMD, Inc. stock logo
NAKA
KindlyMD
$4.45
-5.7%
$7.67
$3.33
▼
$23.46
$86.60M16.03186,334 shs125,194 shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$1.42
-13.4%
$2.06
$0.95
▼
$9.08
$53.58M1.431.48 million shs1.11 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Solana Company stock logo
HSDT
Solana
-0.30%-10.41%-27.01%-12.10%-61.98%
LITS
Lite Strategy
-7.20%-17.01%-30.89%-15.45%-58.17%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
+2.83%-19.59%-33.80%-22.11%-78.68%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-4.09%-15.03%-3.24%-18.41%-41.01%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Solana Company stock logo
HSDT
Solana
$1.63
-0.3%
$2.32
$1.19
▼
$4.36
$102.82M1.1623,709 shs231,770 shs
LITS
Lite Strategy
$0.81
+1.6%
$1.15
$0.69
▼
$1.99
$23.75M0.17280,907 shs148,449 shs
KindlyMD, Inc. stock logo
NAKA
KindlyMD
$4.45
-5.7%
$7.67
$3.33
▼
$23.46
$86.60M16.03186,334 shs125,194 shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$1.42
-13.4%
$2.06
$0.95
▼
$9.08
$53.58M1.431.48 million shs1.11 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Solana Company stock logo
HSDT
Solana
-0.30%-10.41%-27.01%-12.10%-61.98%
LITS
Lite Strategy
-7.20%-17.01%-30.89%-15.45%-58.17%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
+2.83%-19.59%-33.80%-22.11%-78.68%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-4.09%-15.03%-3.24%-18.41%-41.01%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Solana Company stock logo
HSDT
Solana
2.25
Hold$3.50114.72% Upside
LITS
Lite Strategy
1.00
SellN/AN/A
KindlyMD, Inc. stock logo
NAKA
KindlyMD
2.50
Moderate Buy$19.00326.97% Upside
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest LITS, HSDT, NAKA, and THAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
KindlyMD, Inc. stock logo
NAKA
KindlyMD
Lower Price TargetBuy$13.00 ➝ $10.00
11/12/2026
Solana Company stock logo
HSDT
Solana
Lower Price TargetBuy$4.00 ➝ $3.00
11/4/2026
KindlyMD, Inc. stock logo
NAKA
KindlyMD
Reiterated RatingSell (D-)
10/26/2026
LITS
Lite Strategy
UpgradeSell (E+) ➝ Sell (D-)
10/15/2026
Solana Company stock logo
HSDT
Solana
Reiterated RatingSell (E+)
10/9/2026
LITS
Lite Strategy
DowngradeSell (D-) ➝ Sell (E+)
9/24/2026
LITS
Lite Strategy
UpgradeSell (E+) ➝ Sell (D-)
9/22/2026
Solana Company stock logo
HSDT
Solana
Boost Price TargetBuy$3.50 ➝ $4.00
9/22/2026
KindlyMD, Inc. stock logo
NAKA
KindlyMD
Boost Price TargetBuy$11.00 ➝ $13.00
9/8/2026
LITS
Lite Strategy
DowngradeSell (D-) ➝ Sell (E+)
9/3/2026
Solana Company stock logo
HSDT
Solana
Reiterated RatingBuy
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Solana Company stock logo
HSDT
Solana
$14.74M6.96N/AN/A$4.23 per share0.39
LITS
Lite Strategy
$65.30M0.37N/AN/A$1.90 per share0.42
KindlyMD, Inc. stock logo
NAKA
KindlyMD
$1.82M44.87N/AN/A$17.67 per share0.25
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/A$0.68 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Solana Company stock logo
HSDT
Solana
-$40.89M$3.740.44N/AN/A2,040.43%128.12%122.51%N/A
LITS
Lite Strategy
-$71.15M-$1.38N/AN/AN/AN/A-115.42%-113.12%N/A
KindlyMD, Inc. stock logo
NAKA
KindlyMD
-$52.23M-$14.98N/AN/AN/A-1,067.93%-73.53%-46.28%N/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%N/A

Latest LITS, HSDT, NAKA, and THAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
KindlyMD, Inc. stock logo
NAKA
KindlyMD
-$0.49$4.07+$4.56$4.07N/A($1.93) million
11/11/2026Q3 2026
Solana Company stock logo
HSDT
Solana
-$0.01$1.17+$1.18$1.17$2.85 million$3.36 million
11/5/2026Q1 2027
LITS
Lite Strategy
N/A$0.48N/A$0.48N/AN/A
9/28/2026Q4 2026
LITS
Lite Strategy
N/A-$0.38N/A-$0.3760N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Solana Company stock logo
HSDT
Solana
N/AN/AN/AN/AN/A
LITS
Lite Strategy
N/AN/AN/AN/AN/A
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/AN/AN/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Solana Company stock logo
HSDT
Solana
N/A
2.33
2.33
LITS
Lite Strategy
N/A
3.64
3.64
KindlyMD, Inc. stock logo
NAKA
KindlyMD
0.18
0.23
0.23
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/A
4.98
4.98

Institutional Ownership

CompanyInstitutional Ownership
Solana Company stock logo
HSDT
Solana
18.63%
LITS
Lite Strategy
52.38%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.16%

Insider Ownership

CompanyInsider Ownership
Solana Company stock logo
HSDT
Solana
14.40%
LITS
Lite Strategy
1.60%
KindlyMD, Inc. stock logo
NAKA
KindlyMD
24.08%
Tharimmune, Inc. stock logo
THAR
Tharimmune
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Solana Company stock logo
HSDT
Solana
2162.89 million53.83 millionOptionable
LITS
Lite Strategy
529.89 million29.41 millionOptionable
KindlyMD, Inc. stock logo
NAKA
KindlyMD
N/A18.35 million13.93 millionOptionable
Tharimmune, Inc. stock logo
THAR
Tharimmune
237.73 million35.20 millionNot Optionable

Recent News About These Companies

Tharimmune Inc.
Tharimmune Approved as Super Validator on Canton Network
Tharimmune appoints Jacob Asbury as CFO
Tharimmune Appoints Jacob Asbury as New CFO
Crypto Company Creates Bizarre Drug

New MarketBeat Followers Over Time

Media Sentiment Over Time

Solana stock logo

Solana NASDAQ:HSDT

$1.63 -0.01 (-0.31%)
Closing price 04:00 PM Eastern
Extended Trading
$1.62 -0.01 (-0.92%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

Lite Strategy NASDAQ:LITS

$0.81 +0.01 (+1.56%)
Closing price 04:00 PM Eastern
Extended Trading
$0.81 +0.01 (+0.84%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

KindlyMD stock logo

KindlyMD NASDAQ:NAKA

$4.45 -0.27 (-5.72%)
As of 04:00 PM Eastern

Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.

Tharimmune stock logo

Tharimmune NASDAQ:THAR

$1.42 -0.22 (-13.41%)
As of 11/17/2026

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.